Table 1.
Patient Baseline Characteristics
| Demographics | Whites n=4,460 |
Blacks n=235 |
P |
|---|---|---|---|
| Mean age at diagnosis | 74.9 | 74.4 | NS |
| Age groups | 0.025 | ||
| Age 66-69 | 22.5% | 26.8% | |
| Age 70-74 | 28.1% | 33.2% | |
| Age 75-79 | 27.0% | 18.7% | |
| Age 80-84 | 15.3% | 12.8% | |
| Age 85 or greater | 7.0% | 8.5% | |
| Stage | 0.007 | ||
| Stage III | 66.5% | 57.9% | |
| Stage IV | 33.5% | 42.1% | |
| Comorbidities | |||
| CHF | 5.2% | 9.4% | 0.006 |
| Diabetes | 12.7% | 29.9% | <.001 |
| Diabetes with sequelae | 2.1% | 6.4% | <.001 |
| Charlson Comorbidity Score | 0.56 | 0.93 | <.001 |
| Comorbidity Groups | <.001 | ||
| No Comorbidity | 65.0% | 47.2% | |
| 1 Comorbidity | 22.3% | 30.6% | |
| 2 Comorbidities | 7.7% | 11.9% | |
| 3+ Comorbidities | 5.0% | 10.2% | |
| Histology | 0.351 | ||
| Adenocarcinoma | 81.8% | 81.3% | |
| Clear Cell | 1.9% | ≤4.7% | |
| Endometroid | 8.1% | 7.7% | |
| Mucinous | 3.7% | 6.0% | |
| Other Epithelian | 4.6% | ≤4.7% | |
| Treatment | <.0001 | ||
| Complete Treatment | 67.8% | 54.0% | |
| Incomplete Treatment | 32.2% | 46.0% | |
| - Surgery only | 18.3% | 28.1% | <0.001 |
| - Surgery + 5 or less Chemotherapy cycles |
13.9% | 17.9% | NS |
| Debulking surgery (SEER code) | 29.1% | 26.7% | NS |
| Grade | NS | ||
| Grade 1 | 3.1% | ≤4.7% | |
| Grade 2 | 15.9% | 17.0% | |
| Grade 3 | 50.6% | 44.7% | |
| Grade 4 | 13.0% | ≤12.0% | |
| Unknown grade | 17.4% | 24.3% | |
| SEER Region | <.001 | ||
| Northeast | 20.9% | 16.2% | |
| Midwest | 19.5% | 30.6% | |
| South | 15.2% | 30.2% | |
| West | 44.5% | 23.0% | |
NS, not significant; SEER, Surveillance, Epidemiology, and End Results.